Reports
Sale
Global Infectious Disease Molecular Diagnostics Market Size: By Product: Instruments, Reagents, Services; By Technology: Polymerase Chain Reaction (PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Others; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Infectious Disease Molecular Diagnostics Market Size
The global infectious disease molecular diagnostics market was valued at USD 35.87 billion in 2023, driven by the increasing geriatric population, rising incidence of infectious diseases and technological advancements in diagnostics devices across the globe. The market is expected to grow at a CAGR of 3.20% during the forecast period of 2024-2032, with the values likely to attain USD 47.62 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Infectious Disease Molecular Diagnostics Market Outlook
- According to an article published by World Health Organization, an estimated 354 million people worldwide live with hepatitis B or C. The rising prevalence of infectious diseases globally, such as HIV/AIDS, hepatitis, tuberculosis, and respiratory infections and advances in molecular diagnostic technologies are the major drivers for the growth of the market.
- The government initiatives, screening programs and awareness campaigns aimed at controlling the spread of infectious diseases are propelling the market growth. These efforts emphasize the importance of early detection and treatment, spurring the adoption of molecular diagnostics technologies.
- The advances in molecular diagnostic technologies, such as PCR (polymerase chain reaction), nucleic acid amplification techniques, have revolutionized infectious disease diagnostics, which leads to increase in market growth.
Global Infectious Disease Molecular Diagnostics Market Overview
Infectious disease molecular diagnostic devices include specialized instruments or platforms designed for the detection and identification of infectious agents, such as viruses, bacteria, fungi, and parasites, through molecular methods. These devices employ various molecular diagnostic technologies to amplify and analyze nucleic acids (e.g., DNA or RNA) specific to pathogens present in clinical samples obtained from patients.
The global burden of infectious diseases continues to increase due to factors such as population growth and antimicrobial resistance. As a result, there is a growing need for accurate and rapid diagnostic tests to identify pathogens responsible for infection. Moreover, governments, healthcare systems, public health agencies are investing in molecular diagnostics to enhance their capacity for early detection, surveillance, and containment of outbreaks.
There is a growing demand for point-of-care (POCT) molecular diagnostic tests that can deliver rapid results at the bedside or in community settings. POCT solutions enable timely diagnosis, treatment initiation, and containment of infectious diseases, particularly in resource-limited areas which is expected to create great opportunities for the growth of the market.
Global Infectious Disease Molecular Diagnostics Market Growth Drivers
Rising Demand for Diagnostics Solution
As the incidence of infectious diseases increases, there is a corresponding rise in the demand for diagnostic solutions to identify pathogens causing these diseases. Molecular diagnostics offer high sensitivity and specificity, enabling healthcare providers to detect infectious agents with greater accuracy than traditional methods, such as culture-based techniques.
In the face of outbreaks or epidemics, early detection and surveillance are crucial for controlling the spread of infectious diseases. Molecular diagnostics facilitate early identification of pathogens, allowing for prompt intervention measures. The urgency to contain outbreaks drives the adoption of molecular diagnostic tests, thereby boosting market value.
Surge in Infectious Diseases
According to the World Health Organization’s (WHO) annual estimates, there are globally 300–500 million cases of malaria, 333 million cases of sexually transmitted diseases (syphilis, gonorrhea, chlamydia, and trichomonas), 33 million cases of HIV/AIDS, 14 million people infected with tuberculosis, and 3–5 million cases of cholera. The increase in infectious diseases driving demand for diagnostic solutions, prompting technological advancements, expanding testing capabilities, attracting funding, and raising public awareness about the importance of early detection and surveillance.
Increasing Technological Innovations Expected to Propel Infectious Disease Molecular Diagnostics Market Demand
Technological advancements play a pivotal role in driving growth in the market of infectious disease molecular diagnostics by enhancing the performance, accessibility, and versatility of diagnostic tests. Techniques such as real-time PCR, digital PCR, and next-generation sequencing (NGS) enable the detection of low levels of pathogens in clinical samples, improving diagnostic accuracy and reducing false-negative results. Multiplex assays allow the simultaneous detection of multiple pathogens or genetic targets in a single test, offering significant time and cost savings compared to traditional single-target assays.
Hence, the technological advancements continue to shape the landscape of infectious disease molecular diagnostics, driving innovation, improving performance, and expanding the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Infectious Disease Molecular Diagnostics Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Key Trends |
| Expansion of Point-of-Care Testing | There's a growing trend towards the adoption of point of care molecular diagnostics, driven by the need for rapid and decentralized testing. Advancements such as portable molecular diagnostic devices are being developed to enable on-site testing in various settings, including clinics, emergency departments, and remote areas with limited access to laboratory facilities, contributing to market growth. For instance, several RT-PCR systems that use micro fluidic technology including Cepheid GeneXpert have been granted the clinical laboratory improvement amendment (CLIA) waiver by the United States Food and Drug administration (FDA), which allowing their use in POC settings. |
| Integration of Next Generation Sequencing | Next-generation sequencing (NGS) technologies are increasingly being integrated into infectious disease molecular diagnostics workflows, enabling comprehensive genomic analysis of pathogens. NGS offers insights into pathogen evolution, antimicrobial resistance, and outbreak investigation, driving its adoption in clinical and public health settings. The increasing technological advancements are augmenting the growth of the market. |
| Rise in Strategic Partnerships | The infectious disease molecular diagnostics market value is influenced by strategic mergers and acquisitions activities among manufacturers, healthcare providers, and technology companies that are driving innovation and fostering market expansion. These collaborations are accelerating the development of advanced products and augmenting the market reach globally. For instance, in April 2023, ALPCO-GeneProof and Thermo F isher announced a strategic partnership intended to bring TaqPath Menu-GeneProof PCR kits to the market. The partnership combined the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust supply chain and support systems. |
Global Infectious Disease Molecular Diagnostics Market Segmentation
Market Breakup by Product
- Instruments
- Benchtop
- Portable
- Reagents
- Services
Market Breakup by Technology
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Chips and Microarrays
- Mass Spectrometry
- Sequencing
- Transcription Mediated Amplification
- Others
Market Breakup by Application
- Respiratory Diseases
- Gastrointestinal Tract Infections
- Sexually Transmitted Infections
- Drug Resistance Diseases
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Infectious Disease Molecular Diagnostics Market Share
Market Segmentation Based on Technology is Anticipated to Witness Substantial Growth
By technology, the market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), chips and microarrays, mass spectrometry, sequencing, transcription mediated amplification and others. The polymerase chain reaction (PCR) segment is dominating the market as it is one of the most widely used and established technologies in infectious disease molecular diagnostics. It allows for the amplification and detection of specific DNA or RNA sequences of pathogens with high sensitivity and specificity. Real-time PCR enables quantitative measurement of target nucleic acids and is commonly used for viral load monitoring and detection of bacterial, viral, and fungal infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Infectious Disease Molecular Diagnostics Market Analysis by Region
Based on region, the market covers North America, Europe, Asia Pacific, Latin America, as well as Middle East and Africa. North America is dominating the market share due to increasing technological innovation. North America, particularly United States is a leading hub for innovation and research in molecular diagnostics. Moreover, the government agencies, and private investors in North America allocate significant funding and resources to support research and development in infectious disease diagnostics market.
Europe also holds a significant infectious disease molecular diagnostics market value due to region's robust healthcare infrastructure supports the adoption and integration of molecular diagnostic technologies into routine clinical practice, facilitating widespread testing for infectious diseases across various healthcare settings. Additionally, Asia Pacific is expected to witness substantial market growth fueled by the growing patient pool suffering from infectious diseases and increasing collaboration and funding initiatives.
Leading Players in the Global Infectious Disease Molecular Diagnostics Market
The key features of the market report include patent analysis and strategic initiatives including partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:
Becton, Dickinson and Company
BD is a leading global medical technology company that offers a wide range of products and solutions, including infectious disease molecular diagnostic devices. BD has a significant presence in the infectious disease molecular diagnostics market, offering innovative solutions to healthcare providers, laboratories, and public health agencies worldwide.
BioMérieux SA
BioMérieux is a prominent global leader in in-vitro diagnostics, including molecular diagnostics for infectious diseases. The company offers a range of innovative molecular diagnostic devices designed to detect and identify pathogens with accuracy and efficiency.
QIAGEN
QIAGEN is a leading global provider of molecular diagnostics solutions, offering a range of innovative products and platforms for the detection and identification of infectious diseases.
Other key players in the market include F. Hoffmann-La Roche Ltd., Abbott, Agilent Technologies, Inc., Danaher Corporation, Hologic, Inc., Sysmex Corporation, and Illumina, Inc. among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Global Infectious Disease Molecular Diagnostics Market Report
- What was the global infectious disease molecular diagnostics market value in 2023?
- What is the global infectious disease molecular diagnostics market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on product?
- What is market segmentation based on technology?
- What is market segmentation based on application?
- What are the major factors aiding the global infectious disease molecular diagnostics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence of infectious diseases affect the market landscape?
- How does the growing technological advancements impact the market size?
- How do the increasing trend of POC testing affect the market landscape?
- Which application area is expected to have a high market value in the coming years?
- Who are the key players involved in the infectious disease molecular diagnostics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Infectious Disease Molecular Diagnostics Market Overview
3.1 Global Infectious Disease Molecular Diagnostics Market Historical Value (2017-2023)
3.2 Global Infectious Disease Molecular Diagnostics Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Infectious Disease Molecular Diagnostics Market Landscape*
5.1 Global Infectious Disease Molecular Diagnostics: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Infectious Disease Molecular Diagnostics: Product Landscape
5.2.1 Analysis by Product
5.2.2 Analysis by Technology
6 Global Infectious Disease Molecular Diagnostics Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Infectious Diseases Molecular Diagnostics Market, Epidemiology Snapshot
7.1 Overview of Global Infectious Disease Incidence Number (2017-2032)
7.2 Incidence Number, By Indication (2017-2032)
7.2.1 Respiratory Diseases
7.2.2 Gastrointestinal Tract Infections
7.2.3 Sexually Transmitted Infections
7.2.4 Others
8 Global Infectious Disease Molecular Diagnostics Market Segmentation (2017-2032)
8.1 Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
8.1.1 Market Overview
8.1.2 Instruments
8.1.2.1 Benchtop
8.1.2.2 Portable
8.1.3 Reagents
8.1.4 Services
8.2 Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Polymerase Chain Reaction (PCR)
8.2.3 In Situ Hybridization
8.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.2.5 Chips and Microarrays
8.2.6 Mass Spectrometry
8.2.7 Sequencing
8.2.8 Transcription Mediated Amplification
8.2.9 Others
8.3 Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
8.3.1 Market Overview
8.3.2 Respiratory Diseases
8.3.3 Gastrointestinal Tract Infections
8.3.4 Sexually Transmitted Infections
8.3.5 Drug Resistance Diseases
8.3.6 Others
8.4 Global Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals
8.4.3 Specialty Clinics
8.4.4 Diagnostic Laboratories
8.4.5 Research Institutes
8.4.6 Others
8.5 Global Infectious Disease Molecular Diagnostics Market (2017-2032) by Region
8.5.1 Market Overview
8.5.2 North America
8.5.3 Europe
8.5.4 Asia Pacific
8.5.5 Latin America
8.5.6 Middle East and Africa
9 North America Infectious Disease Molecular Diagnostics Market (2017-2032)
9.1 North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
9.1.1 Market Overview
9.1.2 Instruments
9.1.2.1 Benchtop
9.1.2.2 Portable
9.1.3 Reagents
9.1.4 Services
9.2 North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Polymerase Chain Reaction (PCR)
9.2.3 In Situ Hybridization
9.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
9.2.5 Chips and Microarrays
9.2.6 Mass Spectrometry
9.2.7 Sequencing
9.2.8 Transcription Mediated Amplification
9.2.9 Others
9.3 North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
9.3.1 Market Overview
9.3.2 Respiratory Diseases
9.3.3 Gastrointestinal Tract Infections
9.3.4 Sexually Transmitted Infections
9.3.5 Drug Resistance Diseases
9.3.6 Others
9.4 North America Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals
9.4.3 Specialty Clinics
9.4.4 Diagnostic Laboratories
9.4.5 Research Institutes
9.4.6 Others
9.5 North America Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
9.5.1 United States of America
9.5.2 Canada
10 Europe Infectious Disease Molecular Diagnostics Market (2017-2032)
10.1 Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
10.1.1 Market Overview
10.1.2 Instruments
10.1.2.1 Benchtop
10.1.2.2 Portable
10.1.3 Reagents
10.1.4 Services
10.2 Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Polymerase Chain Reaction (PCR)
10.2.3 In Situ Hybridization
10.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
10.2.5 Chips and Microarrays
10.2.6 Mass Spectrometry
10.2.7 Sequencing
10.2.8 Transcription Mediated Amplification
10.2.9 Others
10.3 Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
10.3.1 Market Overview
10.3.2 Respiratory Diseases
10.3.3 Gastrointestinal Tract Infections
10.3.4 Sexually Transmitted Infections
10.3.5 Drug Resistance Diseases
10.3.6 Others
10.4 Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Specialty Clinics
10.4.4 Diagnostic Laboratories
10.4.5 Research Institutes
10.4.6 Others
10.5 Europe Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
10.5.1 United Kingdom
10.5.2 Germany
10.5.3 France
10.5.4 Italy
10.5.5 Others
11 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032)
11.1 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
11.1.1 Market Overview
11.1.2 Instruments
11.1.2.1 Benchtop
11.1.2.2 Portable
11.1.3 Reagents
11.1.4 Services
11.2 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Polymerase Chain Reaction (PCR)
11.2.3 In Situ Hybridization
11.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
11.2.5 Chips and Microarrays
11.2.6 Mass Spectrometry
11.2.7 Sequencing
11.2.8 Transcription Mediated Amplification
11.2.9 Others
11.3 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
11.3.1 Market Overview
11.3.2 Respiratory Diseases
11.3.3 Gastrointestinal Tract Infections
11.3.4 Sexually Transmitted Infections
11.3.5 Drug Resistance Diseases
11.3.6 Others
11.4 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Specialty Clinics
11.4.4 Diagnostic Laboratories
11.4.5 Research Institutes
11.4.6 Others
11.5 Asia Pacific Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 ASEAN
11.5.5 Australia
11.5.6 Others
12 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032)
12.1 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
12.1.1 Market Overview
12.1.2 Instruments
12.1.2.1 Benchtop
12.1.2.2 Portable
12.1.3 Reagents
12.1.4 Services
12.2 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
12.2.1 Market Overview
12.2.2 Polymerase Chain Reaction (PCR)
12.2.3 In Situ Hybridization
12.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
12.2.5 Chips and Microarrays
12.2.6 Mass Spectrometry
12.2.7 Sequencing
12.2.8 Transcription Mediated Amplification
12.2.9 Others
12.3 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
12.3.1 Market Overview
12.3.2 Respiratory Diseases
12.3.3 Gastrointestinal Tract Infections
12.3.4 Sexually Transmitted Infections
12.3.5 Drug Resistance Diseases
12.3.6 Others
12.4 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Specialty Clinics
12.4.4 Diagnostic Laboratories
12.4.5 Research Institutes
12.4.6 Others
12.5 Latin America Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
12.5.1 Brazil
12.5.2 Argentina
12.5.3 Mexico
12.5.4 Others
13 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032)
13.1 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Product
13.1.1 Market Overview
13.1.2 Instruments
13.1.2.1 Benchtop
13.1.2.2 Portable
13.1.3 Reagents
13.1.4 Services
13.2 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Technology
13.2.1 Market Overview
13.2.2 Polymerase Chain Reaction (PCR)
13.2.3 In Situ Hybridization
13.2.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
13.2.5 Chips and Microarrays
13.2.6 Mass Spectrometry
13.2.7 Sequencing
13.2.8 Transcription Mediated Amplification
13.2.9 Others
13.3 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Application
13.3.1 Market Overview
13.3.2 Respiratory Diseases
13.3.3 Gastrointestinal Tract Infections
13.3.4 Sexually Transmitted Infections
13.3.5 Drug Resistance Diseases
13.3.6 Others
13.4 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by End User
13.4.1 Market Overview
13.4.2 Hospitals
13.4.3 Specialty Clinics
13.4.4 Diagnostic Laboratories
13.4.5 Research Institutes
13.4.6 Others
13.5 Middle East and Africa Infectious Disease Molecular Diagnostics Market (2017-2032) by Country
13.5.1 Saudi Arabia
13.5.2 United Arab Emirates
13.5.3 Nigeria
13.5.4 South Africa
13.5.5 Others
14 Regulatory Framework
14.1 Regulatory Overview
14.2 US FDA
14.3 EU EMA
14.4 INDIA CDSCO
14.5 JAPAN PMDA
14.6 Others
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication Year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Strategic Initiatives
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership and Collaborations
16.3 Analysis by Joint Ventures
16.4 Analysis by Leading Players
16.5 Analysis by Geography
17 Supplier Landscape
17.1 Market Share Analysis, By Region (Top 5 Companies)
17.1.1 Market Share Analysis: Global
17.1.2 Market Share Analysis: North America
17.1.3 Market Share Analysis: Europe
17.1.4 Market Share Analysis: Asia-Pacific
17.1.5 Market Share Analysis: Others
17.2 Becton, Dickinson and Company
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 bioMérieux SA
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 QIAGEN
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Abbott
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Danaher Corporation
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Agilent Technologies, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Hologic, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Sysmex Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Illumina, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Global Infectious Disease Molecular Diagnostics Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER